Barrett's Oesophagus

Authored by , Reviewed by Dr Adrian Bonsall | Last edited | Meets Patient’s editorial guidelines

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Barrett's Oesophagus article more useful, or one of our other health articles.

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Synonyms: Barrett's oesophagitis, Barrett's columnar lined oesophagus

Barrett's oesophagus is defined as an oesophagus in which any portion of the normal distal squamous epithelial lining has been replaced by metaplastic columnar epithelium, which is clearly visible endoscopically (>1 cm) above the gastro-oesophageal junction and confirmed histopathologically from oesophageal biopsies[1].

It was first described in 1950 by Barrett, a surgeon.

  • It is often subdivided into short-segment (less than 3 cm) or long-segment (more than 3 cm)[2].
  • Barrett's oesophagus results from chronic gastro-oesophageal reflux. The metaplastic columnar epithelium is at risk of increasing grades of dysplasia leading to invasive adenocarcinoma of the oesophagus[3].
  • Barrett's oesophagus is found in about 2% of the adult population and in 5% of persons with gastro-oesophageal reflux disease (GORD)[4].
  • It is more common in men and much more common in Caucasians (rare in people of African ancestry). The prevalence increases with age and it is more likely to affect those with a postive family history of the condition[5].
  • Most cases remain undiagnosed and the prevalence may be much higher than appreciated.
  • The development of metaplasia to columnar epithelium does not correlate accurately with the degree of oesophageal acid reflux, and other genetic and environmental factors are clearly involved. Both non-steroidal anti-inflammatory drugs (NSAIDS) - by non-selectively blocking COX receptors[6]- and Helicobacter pylori[7]appear to be protective and may be associated with a lower risk of developing oesophageal adenocarcinoma.

Risk factors

  • Patients with chronic GORD are at increased risk of developing the changes of Barrett's oesophagus. The risk increases with longer duration and increased frequency of gastro-oesophageal symptoms.
  • Hiatus hernia is a risk factor and the size of the hernia is correlated with the length of Barrett's oesophagus[8].
  • Some studies indicate a higher prevalence of obesity, smoking and alcohol intake[8].
  • Risk factors for progression to adenocarcinoma include male gender, increasing age, extended segment (>8 cm) disease, intestinal metaplasia, duration of reflux history, early age of onset of GORD, duodeno-gastro-oesophageal reflux, mucosal damage (ulceration and stricture) and family history[1, 4].
  • Some patients may not have any symptoms. Symptoms of gastro-oesophageal reflux and strictures are less common in the affected oesophageal segment.
  • The classic history is a middle-aged Caucasian male with a long history of gastro-oesophageal reflux and, occasionally, dysphagia[2].
  • Histological corroboration of endoscopically visible columnarisation is the most accurate method of diagnosis[1]. In cases of erosive oesophagitis, it is important to treat the oesophagitis first to ensure there is no Barrett's mucosa underneath the inflammation.
  • When high-grade dysplasia or cancer is found on surveillance endoscopy, endoscopic ultrasound is advisable to evaluate for surgical resectability[2].
  • A patient with a columnar-lined distal oesophagus without confirmed intestinal metaplasia on biopsy must be followed up with further endoscopies and biopsies.

Editor's note

Dr Sarah Jarvis, 2nd November 2020

Balloon cryotherapy for Barrett's oesophagus
The National Institute for Health and Care Excellence (NICE) has issued new guidance[9]on the use of balloon cryoablation for Barrett's oesophagus. They recommend that there is inadequate evidence on the safety and efficacy of this procedure. 

Balloon cryotherapy should, therefore, only be used in the context of research and patient selection should be carried out by clinicians experienced in managing Barrett's oesophagus.

The role of surveillance endoscopy is controversial and changing[1, 4]. Oesophageal cancers arising in Barrett's oesophagus detected by surveillance are often early and have an excellent prognosis. There is a paucity of randomised controlled trial (RCT) data on the effect of surveillance but studies demonstrate that surveillance results in earlier cancer staging and improved survival. It is recommended that when surveillance is considered appropriate, it should be performed every 2-5 years in the UK, depending on the length of the affected segment and the presence of intestinal metaplasia[1].

The management of low-grade dysplasia is unclear, although it is recommended that, after two pathologists have confirmed the diagnosis, surveillance be repeated every six months[1].

High-grade dysplasia is associated with a focus of invasive adenocarcinoma in 30-40% of patients. Photodynamic therapy appears to be effective in downgrading the dysplasia when used for high-grade dysplasia. However, its efficacy in preventing the progression of Barrett's oesophagus to invasive cancer is not clear[10]. Photodynamic therapy has been largely superseded by radiofrequency ablation, as recommended in the latest British Society of Gastroenterology (BSG) guidance.

If high-grade dysplasia persists after intensive acid suppression, oesophagectomy in a specialised unit is currently recommended in patients considered fit for surgery. In those unfit for surgery, endoscopic ablation or mucosal resection should be considered[1, 10].


The recommended lifestyle advice is the same as that recommended for patients with GORD:

  • Reduce weight.
  • Stop smoking.
  • Reduce alcohol intake.
  • Raise the head of the bed at night.
  • Take small, regular meals.
  • Avoid hot drinks, alcohol, and eating within three hours of going to bed.
  • Avoid drugs that affect oesophageal motility (nitrates, anticholinergics, tricyclic antidepressants) or damage the mucosa (NSAIDs, potassium salts, alendronate).


  • Available data indicate that long-term proton pump inhibitor (PPI) therapy is effective. Twice-daily PPI therapy may be recommended for patients who do not respond clinically to once-daily therapy. There are no studies that provide evidence that higher doses of PPI therapy provide any increased benefit for prevention of oesophageal adenocarcinoma[2].
  • Review of data - the Aspirin Esomeprazole Chemoprevention Trial (AspECT) - indicates that chemoprevention with aspirin may be the most promising approach for reduction of adenocarcinoma risk, previous studies having shown a protective association between NSAIDs and oesophageal cancer[11].
  • Ablative therapy[10, 12]. The goal of ablative therapy is to destroy the Barrett's epithelium to a sufficient depth to eliminate the intestinal metaplasia and allow regrowth of squamous epithelium. A number of modalities have been tried - eg, photodynamic therapy, argon plasma coagulation, multipolar electrocoagulation and various forms of lasers. There is no direct evidence to suggest that there is a reduction in cancer risk in patients after mucosal ablation therapy[13]. Long-term outcomes have been disappointing in terms of relapse after treatment; however, this form of treatment is still considered to offer the prospect of developing improved intervention for the future[14].


  • Anti-reflux surgeries (eg, Nissen's fundoplication) have not been shown to prevent the progression of Barrett's oesophagus to oesophageal cancer[2].
  • Oesophagectomy is, however, often recommended when severe dysplasia is confirmed[15].
  • The most significant complication is the development of adenocarcinoma in the oesophagus. Recent data suggest that the risk of dysplasia is strongly associated with increasing age of the patient and the segment length of Barrett's oesophagus[16]. The incidence of adenocarcinoma is rising, with current rates in Scotland being the highest reported rates in the world[4].
  • Although Barrett's oesophagus is the only known precursor to oesophageal adenocarcinoma, most patients with Barrett's oesophagus do not develop cancer[17].
  • Barrett's oesophagus has a 2-25% risk of mild-severe dysplasia and a lifetime risk of developing adenocarcinoma of 3% in women and 5% in men[4]. 40-50% of those patients with Barrett's oesophagus and severe dysplasia go on to develop oesophageal adenocarcinoma within five years[14].
  • Barrett's oesophagus is a pre-malignant condition and increases the risk of oesophageal adenocarcinoma to 30-60 times that of the general population[18].
  • Most patients will not develop oesophageal cancer and will die of other causes.
  • 5-10% of those with Barrett's oesophagus will develop adenocarcinoma over 10-20 years[19].
  • In a cohort study of patients with Barrett's oesophagus but not undergoing surveillance, only 2.5% of 155 patients died as a result of oesophageal cancer, with a mean of nine years' follow-up[2].

Endoscopic surveillance for patients with Barrett's oesophagus is described above.

Should patients with heartburn be screened for Barrett's oesophagus?

Chronic heartburn is a risk factor for oesophageal adenocarcinoma and the risk increases with increasing severity and duration of heartburn. However, the absolute risk in individual patients is less than 1 in 1,000 per annum. The latest BSG guidelines recommend that:

  • Screening with endoscopy is not feasible or justified for an unselected population with gastro-oesophageal reflux symptoms.
  • Endoscopic screening can, however, be considered in patients with chronic GORD symptoms and multiple risk factors (at least three of age 50 years or older, white race, male sex, obesity).
  • The threshold of multiple risk factors should, however, be lowered in the presence of a family history including at least one first-degree relative with Barrett's oesophagus or oesophageal adenocarcinoma[1].

However, in view of the increasing incidence of oesophageal adenocarcinoma, the poor results of treatment for established adenocarcinoma and the likely development of better diagnostic tools in the future, screening may be considered worthwhile in the future.

Further reading and references

  1. Fitzgerald RC, di Pietro M, Ragunath K, et al; British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014 Jan63(1):7-42. doi: 10.1136/gutjnl-2013-305372. Epub 2013 Oct 28.

  2. Sharma P, McQuaid K, Dent J, et al; A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004 Jul127(1):310-30.

  3. Flejou JF; Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut. 2005 Mar54 Suppl 1:i6-12.

  4. Jankowski J, Barr H, Wang K, et al; Diagnosis and management of Barrett's oesophagus. BMJ. 2010 Sep 10341:c4551. doi: 10.1136/bmj.c4551.

  5. Sharma N, Ho KY; Risk Factors for Barrett's Oesophagus. Gastrointest Tumors. 2016 Oct3(2):103-108. Epub 2016 Apr 8.

  6. Fitzgerald RC; Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut. 2005 Mar54 Suppl 1:i21-6.

  7. Malfertheiner P, Peitz U; The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut. 2005 Mar54 Suppl 1:i13-20.

  8. Avidan B, Sonnenberg A, Schnell TG, et al; Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci. 2002 Feb47(2):256-64.

  9. Balloon cryoablation for Barrett’s oesophagus; NICE Interventional procedures guidance, October 2020

  10. Fitzgerald RC, di Pietro M, Ragunath K, et al; British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014 Jan63(1):7-42. doi: 10.1136/gutjnl-2013-305372. Epub 2013 Oct 28.

  11. Corley DA, Kerlikowske K, Verma R, et al; Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003 Jan124(1):47-56.

  12. Photodynamic therapy for Barrett's oesophagus; NICE Interventional Procedure Guidance, June 2010

  13. Rees JRE, Lao-Sirieix P, Wong A, Fitzgerald RC. Treatment for Barrett's oesophagus. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD004060. DOI: 10.1002/14651858.CD004060.pub2.

  14. Deviere J; Barrett's oesophagus: the new endoscopic modalities have a future. Gut. 2005 Mar54 Suppl 1:i33-7.

  15. Schuchert MJ, Luketich JD; Management of Barrett's esophagus. Oncology (Williston Park). 2007 Oct21(11):1382-9, 1392

  16. Gopal DV, Lieberman DA, Magaret N, et al; Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci. 2003 Aug48(8):1537-41.

  17. Spechler SJ, Lee E, Ahnen D, et al; Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001 May 9285(18):2331-8.

  18. Lagergren J; Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005 Mar54 Suppl 1:i1-5.

  19. Dyspepsia - proven GORD; NICE CKS, November 2012 (UK access only)